Warehousing re-annotated cancer genes for biomarker meta-analysis

详细信息    查看全文

• 作者：M. Orsini^a ; ^{orsini@crs4.it} ; A. Travaglione^a ; ^{travanto@crs4.it} ; E. Capobianco^b ; ^c ; ^{ecapobianco@med.miami.edu}
• 关键词：Cancer transcriptomics ; Re-annotation ; Data warehousing
• 刊名：Computer Methods and Programs in Biomedicine
• 出版年：2013
• 出版时间：July, 2013
• 年：2013
• 卷：111
• 期：1
• 页码：166-180
• 全文大小：4002 K

文摘

Translational research in cancer genomics assigns a fundamental role to bioinformatics in support of candidate gene prioritization with regard to both biomarker discovery and target identification for drug development. Efforts in both such directions rely on the existence and constant update of large repositories of gene expression data and omics records obtained from a variety of experiments. Users who interactively interrogate such repositories may have problems in retrieving sample fields that present limited associated information, due for instance to incomplete entries or sometimes unusable files. Cancer-specific data sources present similar problems. Given that source integration usually improves data quality, one of the objectives is keeping the computational complexity sufficiently low to allow an optimal assimilation and mining of all the information. In particular, the scope of integrating intraomics data can be to improve the exploration of gene co-expression landscapes, while the scope of integrating interomics sources can be that of establishing genotype-phenotype associations. Both integrations are relevant to cancer biomarker meta-analysis, as the proposed study demonstrates. Our approach is based on re-annotating cancer-specific data available at the EBI's ArrayExpress repository and building a data warehouse aimed to biomarker discovery and validation studies. Cancer genes are organized by tissue with biomedical and clinical evidences combined to increase reproducibility and consistency of results. For better comparative evaluation, multiple queries have been designed to efficiently address all types of experiments and platforms, and allow for retrieval of sample-related information, such as cell line, disease state and clinical aspects.